J INTS BIO, WCLC 2023 – Presentation of Phase 1/2 study of ‘JIN-A02’, a Novel Oral 4th Generation EGFR TKI

SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ — J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI ‘JIN-A02’ was presented at the 2023 IASLC World Conference on Lung Cancer held in Singapore from 9th to 12th September, during the…